We program cells to make the right decisions to beat cancer.

The Problem: The precise geometry of antigen-receptor interactions determines the potency of engineered immune cells when fighting cancer. Existing proteins have not provided the flexibility needed to maximize immune cell activity.

Our Solution: OutSpacers™ are fully human sequences that maximize CAR T cell function, leading to more potent killing of cancer cells. With OutSpacers™ technology, we can create finely tuned CAR designs that achieve optimal immunological synapse geometry to maximize efficacy.

Our diverse OutSpacers™ library allows us to optimize activity for a wide range of binders and antigen pairs. 

The Problem: Cancer cells, together with the immune cells that should be targeting them, produce signaling proteins that turn off the immune response. This dysfunctional microenvironment allows cancer to grow and spread. Pro-inflammatory cytokines, for example, could overcome the TME but pose a significant safety risk to patients when delivered systemically given their potency.
‍
‍Our Solution: Cell therapies with OutSmart™ technology produce designed proteins, such as cytokines, inside the tumor and keep them there. With OutSmart™, the cell therapy bolsters its own activity while also recruiting helpful bystander cells to achieve efficacy without compromising safety.

‍OutSmart™ uses novel promoter elements to regulate gene expression and protein design to customize which cells and signaling pathways are activated.

The Problem: Immune cells naturally turn off when fighting cancer, limiting the effectiveness of current engineered cell therapies. This can lead to cancer progression and relapse.

Our Solution:  OutLast™ technology reprograms cell therapies to make better decisions inside patients with the goal of achieving a durable clinical response. With OutLast™, individual cells regulate themselves without the need for co-therapies to rest and reactivate as needed.

OutLast™ uses novel promoter elements to regulate gene expression and novel designed targeted degraders to regulate protein function.

The Problem: Powerful cell therapies require advanced safety features and technologies to help monitor both manufacturing quality and how cell therapies function inside patients.

Our Solution: With EGFRopt™ technology, cell therapies can be safely controlled by antibodies that target the EGF receptor. This allows them to be deactivated quickly if needed.

EGFRopt™ is a fully human control technology that responds to cetuximab. In vivo studies demonstrate faster & more complete ablation of CAR activity.

‍EGFRopt™ can also be used for other applications including cell selection and quality control during manufacturing.

The Problem: Cancer cells look like healthy cells in many ways, making them difficult to target.

Our Solution: Cell therapies with Co-LOCKR™ technology use logic-gated targeting to recognize the unique antigen fingerprints on the surface of cancer cells, making it possible to safely treat many types of cancers.

Co-LOCKR™ targeting technology achieves single-cell specificity in mixed cell populations. Because we target cancer cells using designed proteins, T cells with Co-LOCKR™ avoid healthy tissues.